JP2018509469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509469A5 JP2018509469A5 JP2017566608A JP2017566608A JP2018509469A5 JP 2018509469 A5 JP2018509469 A5 JP 2018509469A5 JP 2017566608 A JP2017566608 A JP 2017566608A JP 2017566608 A JP2017566608 A JP 2017566608A JP 2018509469 A5 JP2018509469 A5 JP 2018509469A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- active fragment
- use according
- immunologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 238000012261 overproduction Methods 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 3
- 102000009193 Caveolin Human genes 0.000 claims description 2
- 108050000084 Caveolin Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 2
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131343P | 2015-03-11 | 2015-03-11 | |
| US62/131,343 | 2015-03-11 | ||
| PCT/US2016/020864 WO2016144743A1 (en) | 2015-03-11 | 2016-03-04 | Compositions and methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509469A JP2018509469A (ja) | 2018-04-05 |
| JP2018509469A5 true JP2018509469A5 (https=) | 2019-04-18 |
| JP6871876B2 JP6871876B2 (ja) | 2021-05-19 |
Family
ID=56879779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566608A Active JP6871876B2 (ja) | 2015-03-11 | 2016-03-04 | がんを治療するための組成物と方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11279754B2 (https=) |
| EP (1) | EP3268028B1 (https=) |
| JP (1) | JP6871876B2 (https=) |
| CA (1) | CA2979210A1 (https=) |
| WO (1) | WO2016144743A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871876B2 (ja) | 2015-03-11 | 2021-05-19 | ラッシュ ユニヴァーシティ メディカル センター | がんを治療するための組成物と方法 |
| US20230174636A1 (en) * | 2020-05-12 | 2023-06-08 | Rush University Medical Center | Compositions and methods for treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7282204B2 (en) | 2003-03-10 | 2007-10-16 | Schering Corporation | Uses of IL-23 agonists and antagonists; related reagents |
| MY157915A (en) * | 2004-12-21 | 2016-08-15 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses. |
| WO2012159100A1 (en) * | 2011-05-19 | 2012-11-22 | Rush University Medical Center | Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment |
| JP6871876B2 (ja) | 2015-03-11 | 2021-05-19 | ラッシュ ユニヴァーシティ メディカル センター | がんを治療するための組成物と方法 |
-
2016
- 2016-03-04 JP JP2017566608A patent/JP6871876B2/ja active Active
- 2016-03-04 WO PCT/US2016/020864 patent/WO2016144743A1/en not_active Ceased
- 2016-03-04 US US15/551,710 patent/US11279754B2/en not_active Expired - Fee Related
- 2016-03-04 EP EP16762206.7A patent/EP3268028B1/en active Active
- 2016-03-04 CA CA2979210A patent/CA2979210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534933A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2024020298A5 (https=) | ||
| RU2019140356A (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| JP2021514664A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2017510559A5 (https=) | ||
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2019519499A5 (https=) | ||
| RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| RU2015149285A (ru) | Схемы дозирования иммуноконъюгата anti-folr1 | |
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| MY191423A (en) | Binding molecules specific for cd73 and uses thereof | |
| JP2014158469A5 (https=) | ||
| JP2014502955A5 (https=) | ||
| RU2012137505A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| JP2021528047A5 (https=) | ||
| PH12021550859A1 (en) | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | |
| HRP20221149T1 (hr) | Humanizirana antitijela protiv clever-1 i njihova primjena | |
| JP2016504420A5 (https=) |